肿瘤细胞治疗研究
英文原题：Advances in T-Cell-Directed Immunotherapy for Adult Mature B-Cell Lymphoma: A Comprehensive Review of CAR T-Cell and Bispecific Antibody Therapies.
Advances in T-Cell-Directed Immunotherapy for Adult Mature B-Cell Lymphoma: A Comprehensive Review of CAR T-Cell and Bispecific Antibody Therapies.
B细胞淋巴瘤是一组异质性恶性肿瘤，常规治疗后复发率高。
B细胞淋巴瘤是一组异质性恶性肿瘤，常规治疗后复发率高。T细胞介导的免疫疗法，尤其是嵌合抗原受体（CAR）T细胞疗法和T细胞衔接双特异性抗体（BsAbs），通过利用免疫系统靶向恶性细胞，已改变了治疗格局。本综述分析了多种CD19靶向CAR T细胞疗法及新兴CD20 CD3 BsAbs在不同B细胞淋巴瘤亚型中的疗效和安全性特征。尽管这些疗法已显示出高缓解率和持久缓解的潜力，但细胞因子释放综合征、神经毒性和感染等挑战仍然显著。理解这些机制并管理不良事件对于优化临床结局和指导个性化治疗策略的未来研究至关重要。
B-cell lymphomas are a heterogeneous group of malignancies with a high relapse rate after conventional therapies. T-cell-mediated immunotherapies, notably chimeric antigen receptor (CAR) T-cell therapies and T-cell-engaging bispecific antibodies (BsAbs), have transformed treatment paradigms by harnessing the immune system to target malignant cells. This review analyzes the efficacy and safety profiles of several CD19-targeted CAR T-cell therapies and emerging CD20 CD3 BsAbs across various B-cell lymphoma subtypes. While these therapies have demonstrated high response rates and potential for durable remissions, challenges such as cytokine release syndrome, neurotoxicity, and infections remain significant. Understanding these mechanisms and managing adverse effects are crucial for optimizing clinical outcomes and guiding future research in personalized treatment strategies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
